Oncology R&D has been exploding over the past 5 years, and now Google’s venture arm is preparing to place a few explosives to help with the revolution — relying on a new recruit in the Cambridge/Boston branch to assist in fostering the movement.

Eight months after the high-profile scientist and Agios founder David Schenkein started his third career act in biotech, teaming up with Krishna Yeshwant as a general partner in charge of the life sciences portfolio at GV, they’re bringing on board their second entrepreneur-in-residence to help strategize their approach to investing in cancer research. And he has some deep experience in the oncology field.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN

Last year offered a disappointing stretch for biotech, with fewer deals than expected and lots more headwinds. Endpoints News Editor-in-Chief John Carroll sat down with some of the industry’s top dealmakers to explore what happened, and what’s ahead in 2023. This transcript has been edited for brevity and clarity.

John Carroll:

I’d say this is one of the most important conversations that’s going on right now. Particularly, of course, at JP Morgan, because so many people have come here, specifically to get involved in a deal, to see what they can do about a deal, to see what the deal potential is, where things are headed, what the trends are. Everything that we’re going to be covering here in the next hour.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN

Johnson & Johnson’s therapeutics unit Janssen has laid off employees at multiple sites in New Jersey and Pennsylvania, according to posts on LinkedIn.

“We are constantly assessing ways to be more innovative and competitive,” the Big Pharma said in an emailed statement to Endpoints News Thursday morning. “We are evolving amidst a rapidly changing environment to better meet the needs of the patients we serve around the world.”

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN

Parthenon Therapeutics’ CEO and co-founder Laurent Audoly is no longer steering the ship of the cancer biotech, Endpoints News has learned.

Audoly’s departure comes just weeks after co-founder and chief business and operating officer Olga Granaturova left to take on the same posts at Normunity, another privately-held immunotherapy startup. CSO Tamas Oravecz also traded in his CSO hat for the same role at Simcere last August.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN